CD274 and neoplasm: The remarkable clinical responses of PD-L1/PD-1 blockade confirm the crucial role of the PD-L1/PD-1 axis in tumor immune escape and led to the approval of PD-L1/PD-1 inhibitors by the FDA in more than 10 cancer indications (1).